Axsome Therapeutics (AXSM) Gains Buy Rating Amid Smoking Cessation Trial, But Valuation Remains Elevated

gurufocus.com · 2026-08-31

On August 31, 2026, H.C. Wainwright reaffirmed its Buy rating on Axsome Therapeutics Inc (NASDAQ: AXSM) and set a price target of $290 following the company's a

TickrTrends take: Axsome Therapeutics received a buy rating following progress in its smoking cessation trial, though analysts have flagged elevated valuation concerns for the Healthcare sector company. TickrTrends is currently awaiting full valuation data on AXSM, meaning comprehensive metrics needed to assess whether current pricing aligns with fundamentals remain incomplete. For valuation-focused investors, the key question is whether the company's pipeline advancement will justify its current market valuation once full financial analysis becomes available.

Read the full story at gurufocus.com →